Publications from IDPC Members

Results 1 to 12 of 1075

13 December 2025

Beyond numbers: Regional report highlights gaps and resilience in harm reduction across South-Eastern Europe

EHRA provide a comparative assessment of harm reduction across Southeastern Europe, positioning political commitment and financing as critical to closing gaps.

12 November 2025

From forest to dust: Socioeconomic and environmental impacts of the prohibition of the coca and cocaine production chain in the Amazon Basin and Brazil

Intersecção discusses how drug prohibition fuels deforestation, violence, and inequality across the region, linking the 'war on drugs' to the global climate crisis and calling for ecological harm reduction and rights-based regulation.

14 October 2025

Harm reduction in Europe: Histories, choices and hopes - Collection commemorating 20 years of C-EHRN

This collection examines Europe’s harm reduction journey, including early successes, uneven implementation, securitisation, stigma and medicalisation; and proposes a reframed, people-led approach centring wellbeing, acknowledging drug-use benefits, and advancing rights-based reforms.

14 October 2025

Safer drug laws for Aotearoa New Zealand - Pragmatic, evidence-based recommendations for safer drug laws

The New Zealand Drug Foundation urges reform of outdated drug laws, calling for decriminalisation, Māori-led health approaches and investment in harm reduction to build safer, fairer, evidence-based policies for Aotearoa New Zealand.

10 October 2025

It's not so simple: The impact of simple drug possession and trafficking offences on health equity

The HIV Legal Network argues that laws criminalising simple possession and drug trafficking entrench racism and stigma, deepen inequality, and endanger health and safety by pushing drug use into isolation and heightening the risk of overdose.

30 September 2025

European cities on the frontline: Harm reduction and drug policy – needs, best practices and recommendations

C-EHRN highlights how European cities are responding to evolving drug trends through pragmatic, rights-based harm reduction, while fragmented governance and unstable funding continue to undermine capacity.

28 September 2025

Advancing universal health coverage for people who use drugs

EHRA, alongside C-EHRN, EuroNPUD and DPNSEE, state that the exclusion, fragmentation, and underfunding of harm reduction and essential health services within Universal Health Coverage systems cause people who use drugs to experience disproportionately poor health outcomes across Europe.

25 September 2025

Campaign for the elimination of violence against women who use drugs (EVAWUD 2025) - Toolkit

WHRIN's global campaign around the International Day for the Elimination of Violence against Women calls groups worldwide to join the 16 Days of Action with activities highlighting violence against women and gender diverse people who use drugs.

25 September 2025

Punishment over care: The failing drug policy of Moldova - Submission to the UN CESCR

EHRA, Union for Equity and Health, and PULS urge the Committee to interrogate Moldova’s punitive drug policies, which criminalise people who use drugs, restrict health and employment outcomes, and deepen stigma.

4 September 2025

Civil society perspectives on the ASEAN Work Plan on Drugs 2016–2025 – Submission to ASEAN review process

Civil society exposes punitive harms and rights violations, while urging a shift towards health, harm reduction, decriminalisation, justice reform, and sustainable livelihoods.

14 August 2025

Youth RISE: Promoting harm reduction & drug policy reform

Youth RISE explains that current drug education, often focused on fear-mongering and punitive approaches, fails to equip young people with the knowledge and tools they need to stay safe.

28 July 2025

Where there is fruit, there is seed: Scaling up community involvement for integrated, responsive, and sustainable harm reduction

The BOOST team explains how scaling up community-led harm reduction is crucial for achieving equity, impact, and real progress in the HIV response.